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Abstract 27 
Objectives: to evaluate the impact of three specific ruminant (R) milk fats resulting from 28 
modification of the cow's diet on cardiovascular risk factors in healthy volunteers. R-milk fats were 29 
characterized by increased content in total trans fatty acids (R-TFA) and parallel decrease in 30 
saturated fatty acids (SFA).  31 
 32 
Methods: 111 healthy, normolipemic men and women have been recruited for a monocentric, 33 
randomised, double-blind, and parallel intervention, 4-week controlled study. Volunteers consumed 34 
3 experimental products (butter, dessert cream and cookies) made with one of the 3 specific milk 35 
fats (55 g fat/day). During the first week (run-in period), the subjects consumed on a daily basis 36 
dairy products containing 72% SFA/2.85% R-TFA (called “L0”). For the next 3 weeks of the study 37 
(intervention period), the first group continued to consume L0 products. The second group received 38 
dairy products containing 63.3% SFA/4.06% R-TFA (called “L4”), and the third group received 39 
dairy products containing 56.6% SFA/12.16% R-TFA (called “L9”). 40 
 41 
Results: plasma concentrations of HDL-cholesterol was not significantly altered by either diet (p = 42 
0.38). Compared to L0 diet, L4 diet contributed to reduce LDL-cholesterol (-0.14±0.38 mmol/L, p= 43 
0.04), total cholesterol (-0.13±0.50 mmol/L, p = 0.04), LDL-cholesterol/HDL-cholesterol (-44 
0.14±0.36, p = 0.03) and total cholesterol/HDL-cholesterol (-0.18±0.44, p = 0.02). 45 
 46 
Conclusion: different milk fat profiles can change cardiovascular plasma parameters in human 47 
healthy volunteers. A limited increase of the R-TFA/SFA ratio in dairy products is associated with 48 
an improvement in some cardiovascular risk factors. However, a further increase in R-TFA/SFA 49 
ratio has no additional benefit. 50 
 51 
Keywords: Human Nutrition, Lipids, trans fatty acids, milk fat, cardiovascular risk factors, 52 
cholesterol. 53 
 54 
Introduction 55 
Over 2 million people in EU are dying from Cardiovascular disease (CVD) every year(European 56 
Heart Network, 2008). The subsequent cost is estimated to €192 billion /y including direct and 57 
indirect cost. Thus, the reduction of the number of death from CVD is a huge target which could be 58 
reached by a limiting exposure to CVD risk factors. In this respect, dietary fatty acids represent key 59 
factors having a significant impact on health, especially on CVD. Specific effects of clusters or 60 
isolated fatty acids have been extensively studied, with a particular attention paid to saturated (SFA) 61 
and trans (TFA) fatty acids (Ascherio et al., 1999; Gebauer et al., 2007; Hu et al., 1997; Katan et 62 
al., 1995). Reports from different health authorities and agencies recommend a reduction of SFA 63 
and TFA intake (Afssa, 2005; Scientific Panel on Dietetic Products, 2004; Stender and Dyerberg, 64 
2003).   65 
Two meta-analyses tabulating different intervention studies clearly stated that TFA are more 66 
deleterious than SFA, when considering fatty acids’ impact on cardiovascular risk factors  67 
(Ascherio et al., 1999; Mensink et al., 2003). Consequently, the relationship between the 68 
consumption of dietary TFA and the increased risk of CVD has been clearly highlighted (Booker 69 
and Mann, 2008; Dalainas and Ioannou, 2008; Gebauer et al., 2006) . However, all these studies 70 
considered industrially produced TFA isomers (IP-TFA) resulting from partial hydrogenation of 71 
oils, but TFA are also present naturally in ruminant milk fat and meat (R-TFA). R-TFA and IP-TFA 72 
have different isomeric profiles. In IP-TFA, trans-9 18:1 (elaïdic acid) and trans-10 18:1 are the 73 
most important isomers whereas trans-11 18:1 (vaccenic acid) is the major R-TFA isomer (Stender 74 
and Dyerberg, 2004). The R-TFA term comprises total trans fatty acids (all the geometrical isomers 75 
of monounsaturated and polyunsaturated fatty acids having non-conjugated, carbon-carbon double 76 
bonds in the trans configuration., except the Conjugated Linoleic acids (CLA), according to the 77 
Afssa’s definition (Afssa, 2005)  . Until now, only few clinical trials have studied the specific 78 
isomeric effects of TFA (IP-TFA vs. R-TFA) on CVD.  79 
Recently, two concomitant studies were published. In the first one, 38 healthy men were provided 3 80 
meals/d based on 4 experimental diets: high R-TFA (3.7% of daily energy, ≈ 13.3 g/d), moderate R-81 
TFA (1.5% of daily energy, ≈ 5.6 g/d), high IP-TFA (3.7% of daily energy, ≈ 13.3 g/d), and 82 
“control” low total TFA (0.8% of daily energy) for 4 weeks. The consumption of the high IP-TFA 83 
and high R-TFA diets had similar consequences, i.e. elevated LDL-cholesterol concentrations and 84 
decreased HDL-cholesterol levels compared to the consumption of moderate R-TFA or low total 85 
TFA diets (Motard-Belanger et al., 2008). The second one is the TransFact study (Chardigny et al., 86 
2008)  where 40 healthy subjects consumed food items containing either R-TFA or IP-TFA (11–12 87 
g/d, ≈5% of daily energy intake). Different effects on CVD risk factors are reported according to the 88 
2 sources of TFA but the HDL cholesterol–lowering property of TFA was concluded to be specific 89 
to IP-TFA.  90 
Moreover, the consumption for 6 weeks of dairy products naturally enriched in vaccenic acid (the 91 
major R-TFA isomer) (around 1.6% daily energy intake) had no effects on most CVD risk 92 
parameters in middle-aged men (Tricon et al., 2006). Finally, a 18 y-follow-up study found no 93 
association between R-TFA intake and CVD risk factors(Jakobsen et al., 2008). 94 
Modifications of cows’ feeding are able to up-regulate the R-TFA content in milk fat with a 95 
concomitant reduction in SFA (Chilliard and Ferlay, 2004). These changes in milk fat composition 96 
can be considered as a beneficial output (Hu et al., 1997). In that respect during a 5 week 97 
intervention study, Tholstrup et al. showed that a butter rich in vaccenic acid (3.6g/d – around 1% 98 
daily energy intake) and monounsaturated FAs, significantly decreased total and HDL-cholesterol 99 
concentrations in comparison with a conventional butter high in SFA (Tholstrup et al., 2006). From 100 
these combined data, the importance of improving R-TFA to SFA ratio in dairy products is 101 
suggested. The present study aimed at evaluating in healthy volunteers, the impact on CVD risk 102 
factors of milk fats presenting varying ratio between R-TFA and SFA but also MUFA and PUFA. 103 
In this respect, a clinical trial where two-thirds of daily fat intake came from experimental dairy fat 104 
was designed.  105 
Materials and Methods 106 
Materials. Three experimental dairy fats differing in their fatty acid profiles were obtained from 107 
cows fed or not linseed extruded grain or oil; the detailed fatty acid profiles are presented in Table 108 
1. The first one, called “L0” (no linseed supplementation) is the dairy fat with the lowest R-109 
TFA/SFA ratio, i.e. 2.9 and 72 g/100g of fatty acids respectively. The milk was obtained from dairy 110 
cows fed a maize silage diet with cereals based concentrate and soybean meal. The second dairy fat, 111 
“L4” obtained from cows supplemented with 4.1% on DM basis of extruded linseed (Tradi-Lin® 112 
Valorex SAS Combourtillé, France) contained around 4.1 and 63.3 g/100g of R-TFA and SFA, 113 
respectively. Finally, “L9” obtained from cows grazing on autumn grass based on a mixture of 114 
white clover and perennial rye grass and supplemented with 1 kg of linseed oil (SA huilerie 115 
Vandeputte, Mouscron, Belgium) mixed with 5 kg of fresh maize silage. The milk contained around 116 
12.2 and 56.6g /100g of R-TFA and SFA, respectively.  117 
 118 
Subjects. Volunteers meeting the following criteria: age 18-50 y, waist circumference < 94 cm for 119 
men and < 80 cm for women, HDL-C > 1 mmol/L, LDL-C < 4.1 mmol/L and TG < 1.7 mmol/L 120 
were enrolled. The eligibility criteria also included non-smoking, and for women, effective 121 
contraception. Characteristics of the volunteers are summarized in Table 2. 122 
 123 
Sample size recruitement. The main criterion justifying the number of recruited subjects was the 124 
expected L9-induced increase of HDL-cholesterol compared to L0. The difference between L9 and 125 
L0  was calculated using the predictive equation of HDL-cholesterol (Yu et al., 1995) and averaged 126 
δ=2.17 mg/dL. Sample size (n) was then calculated using the formula n = (zα+zβ)2(σ/δ)2) for 127 
comparison of two averages (significance level α was chosen to be 5 % two-sided, leading to zα = 128 
1.96, β was 1-power, and power was set to 80%, leading to zβ = 0.84). According to the TransFact 129 
trial (Chardigny et al., 2006) the within subject standard deviation (SD) on this parameter is 4.5 130 
mg/dL. Therefore, 34 subjects per group were needed to detect significant statistical differences 131 
(p<0.05 two- sided test). To take into account putative drop outs, 37 subjects per group were finally 132 
recruited i.e. a total of 111 healthy volunteers (57 men and 54 women).  133 
 134 
Human intervention design. This study was a controlled, double-blind, randomized trial. It has 135 
been approved by the French authorities “Comité Protection des Personnes” (CPP Auvergne, 136 
Clermont-Ferrand, France, agreement #AU684). For all subjects, written informed consent was 137 
obtained. The Clinical Trial Registration number is NCT00685581. The study design is provided in 138 
Figure 1. During the 3 week duration of the intervention, the volunteers consumed three different 139 
food items prepared with the 3 experimental fats: butter (20 g/d, 80% fat content), dessert cream 140 
(100 g/d, 25% fat content), and cookies (59 g/d, 24% fat content) which corresponded to a total 141 
intake of 55 g of lipid (i.e. two-thirds of the total daily lipid intake). Within a day, the experimental 142 
products could be consumed during any meal or snack. The three food items were prepared with the 143 
three different experimental milk fats (see above). The products were manufactured using the same 144 
batch of experimental fat. Microbiological tests and measurement of both total fat and fatty acid 145 
(FA) profiles were performed before starting the clinical investigation. 146 
During the run-in period (first week, W0), all subjects had to consume L0 food items (Table 1). 147 
Thereafter, the volunteers were randomly allocated to one of the three experimental groups after 148 
gender stratification was performed. For the following 3 week intervention period, the first group 149 
was maintained on the L0 dietary supplementation, whereas the second and the third groups 150 
received food items produced from the L4 and the L9 experimental fats, respectively (Figure 1). 151 
Fatty acid profile of L9 fat (Table 1) was designed so that the total TFA intake contributed to 152 
around 3.1% of daily energy intake (Table 3), which is 2.1% higher than the level recommended by 153 
the French authorities (i.e. 2% of TFA excluding CLA of daily energy intake (Afssa, 2005)). 154 
The dietician gave instructions to subjects in a documented form to avoid foods containing IP-TFA 155 
and ruminant fat. The only source of TFA was the experimental products (R-TFA). All the 156 
volunteers were asked to avoid canteens or restaurants during the trial.  157 
  158 
Measurements. Subjects attended the laboratory for measurements and blood samples the day after 159 
W0 (day 1 of W1) and the day after W3 (day 1 of W4) (Figure 1). Weight was measured at each 160 
visit after an overnight fast of at least 12 h, using the same calibrated digital scale with participant 161 
dressed in light indoor clothing without shoes. Blood were sampled after an 11h to 15h overnight 162 
fast. Plasma was obtained by centrifugation, aliquoted and stored at -80°C until further analyses. 163 
The subjects recorded their dietary intake (foods and drinks) during 5 consecutive days, including 3 164 
week days and 2 week end days, during the run-in period (W0) and during the last week of the 165 
intervention (W3). Data were coded and analyzed by a dietician using computerized nutrient 166 
databases (GENI Micro6.0, Villers-les- Nancy, France). 167 
 168 
Biochemical analyses. HDL-cholesterol, total cholesterol, triglycerides, apolipoprotein A1, 169 
apolipoprotein B were measured by enzymatic assays using a Konelab 20 analyser (Thermo 170 
Electron SA, Cergy-Pontoise, France). LDL-cholesterol concentration was calculated by the 171 
Friedewald equation. In order to assess the compliance, plasma phospholipids FA profiles were 172 
characterized after plasma lipid extraction and fatty acid methylation. Fatty acid methyl ester 173 
profiles were analysed and identified by gas chromatography (Trace GC 2000 Series, 174 
ThermoFinnigan, France). The detailed analytical conditions were already reported (Roy et al., 175 
2006). Cholesteryl ester transfer protein (CETP) activity was measured by fluorimetry using 176 
commercial kits. Fibrinogen was assessed using a turbidimetric assay (BioDirect, La Villeneuve, 177 
France). 178 
 179 
Assessment of subjects’ compliance. Subject compliance was assessed by a questionnaire and by 180 
analysis of the concentration of total trans-18:1 and vaccenic acid in plasma phospholipids 181 
(Mansour et al., 2001). The mean baseline vaccenic acid concentration in phospholipids was 0.098 182 
± 0.027 (mean ± standard deviation) g/100 g total fatty acids with no significant effect observed 183 
between groups. At the end of the experimental periods, the average concentrations of vaccenic acid 184 
found in plasma phospholipids were 0.160 ± 0.045, 0.252 ± 0.077 and 0.616 ± 0.184 g/100 g total 185 
fatty acids for L0, L4 and L9 diet respectively. It was statistically different between the 3 groups (2-186 
way ANOVA, diet: p<0.0001, gender p = 0.489 interaction p = 0.473; post-hoc tests: L0, L4 p = 187 
0.002; L0, L9 p<0.0001 and L4, L9 p < 0.0001). 188 
 189 
Statistical Methods. Values are expressed as means± Standard Deviation (SD). Statistical analysis 190 
was performed using the Statview version 5.0 software (SAS Institute Inc., Cary, NC). The One 191 
way ANOVA procedure was used to determine difference in baseline parameters for the groups. 192 
Differences between final and baseline measurements among the three groups were tested by a two-193 
way ANOVA, including diet and gender as factors. If the main effects were significant (p<0.05), 194 
PLSD Fisher's test was applied for multiple comparisons (post hoc test). We decided to present the 195 
results on the per-protocol data set because 3 subjects had already withdrawn during the run-in 196 
period before the first measurements (for personal reasons and because of time constraints) and one 197 
subject was excluded because he was not compliant. Compliance to the protocol was a primary 198 
outcome in the analysis, showing that per-protocol analysis could be performed on the 107 subjects 199 
who completed the study (Figure 2). 200 
 201 
Results 202 
 203 
Dietary intake. During the intervention period, the dietary intake was similar in each experimental 204 
group with no gender effect (Table 3). As expected, SFA, PUFA and TFA intake were significantly 205 
different between L0, L4, and L9 diets with no gender effects (Table 3).  206 
 207 
Plasma lipids, apolipoproteins. Considering the primary outcome i.e. plasma concentrations of 208 
HDL-cholesterol, no significant change was evidenced between the three groups. However 209 
compared to L0 diet, L4 diet contributed to reduce total cholesterol (p= 0.037), LDL-cholesterol (p 210 
= 0.040), LDL-cholesterol/HDL-cholesterol ratio (p = 0.028), and total cholesterol/HDL-cholesterol 211 
ratio (p= 0.016), whereas L9 diet did not alter most of these parameters (Table 4).  212 
Plasma ApoB concentration tended to be reduced in the L4 group compared to the L0 group, but 213 
without reaching the level of significance (p = 0.065). 214 
No statistical differences appeared for all the others parameters presented in Table 4. 215 
 216 
Discussion 217 
The impact of R-TFA on CVD risk markers is a major issue for human nutritional 218 
recommendations. Changing the level of R-TFA bio-synthesis in the cows’ rumen is associated 219 
with a large panel of changes in milk fatty acid content. Our study aimed therefore at examining the 220 
metabolic effects of experimental milk fats which represent the widest range of putative milk fatty 221 
acid profiles resulting from different cows’ feeding strategies. Major finding showed that the 222 
consumption of dairy fat containing 63.3% SFA and 3.5% trans-18:1 (L4 diet) improved some 223 
CVD risk factors for healthy volunteers in comparison with a typical dairy fat (72% SFA, 2.5% 224 
trans-18:1 –L0 diet). It is illustrated by a decrease in total cholesterol, LDL-cholesterol, total 225 
cholesterol/HDL-cholesterol ratio and LDL-cholesterol/HDL-cholesterol ratio. We observed a 226 
change by 0.18 units in the ratio of total cholesterol/HDL cholesterol between L0 diet and L4 diet. 227 
As reported by Stampfer et al.  (Stampfer et al., 1991), we calculate that this change can be 228 
associated to a 9.5% decrease in the risk of myocardial infarction, which is in the same range as the 229 
replacement of 1334 mg trans α-linolenic acid by dietary cis α-linolenic  (Vermunt et al., 2001). 230 
Moreover, our results show that the consumption for 3 weeks of the L9-dairy fat, which contains 231 
less SFA (56.6%) and more trans-18:1 (9.5%) compared to the L0 diet, induces no significant 232 
changes in plasma markers of CVD (Table 4). In addition, the ratio between total and HDL-233 
cholesterol was significantly increased after 3 weeks of L9-dairy fat compared to L4 diet (p = 234 
0.029). These data suggest that whereas mild increase in R-TFA/SFA ratio in milk fat may be 235 
beneficial compared to L0 diet, further increase in R-TFA/SFA ratio does not provide additional 236 
benefit regarding the CVD risk factors. 237 
In a study where SFA intake was maintained constant (around 18% of energy intake), a 1.5% total 238 
energy intake as R-TFA failed to alter any CVD risk factor (Motard-Belanger et al., 2008). 239 
Interestingly in healthy moderately overweight men and women, Rivellese et al. showed that 240 
decreasing SFA intake by 8% (from 17.6 to 9.6% total energy intake) and increasing in 241 
compensation MUFA intake (from 13.1 to 21.2% total energy intake) induced a reduction in plasma 242 
LDL-cholesterol concentration (-0.38 mmol/L)  (Rivellese et al., 2003). In our present study, milk 243 
fats were characterized by different levels in both R-TFA and SFAs, a higher R-TFA level being 244 
associated with a lower SFA content. Notably, high R-TFA/SFA ratio was also associated with 245 
enhanced MUFA and PUFA intake. These combined changes in milk fat composition could 246 
therefore partially explain the LDL-cholesterol reduction observed after the consumption of the L4 247 
diet in comparison with L0 (see Table 4). Our present results are in agreement with the results of 248 
Poppit et al. (Poppitt et al., 2002)   and Seidel et al.(Seidel et al., 2005). Briefly, Poppit et al. 249 
(Poppitt et al., 2002) reported a significant decrease in both total and LDL-cholesterol in plasma 250 
from healthy men after consuming a modified butter-fat (-5 units of percent total energy intake of 251 
SFA and +2 units of total energy intake of MUFA) for 3 weeks. Seidel et al. (Seidel et al., 2005) 252 
demonstrated beneficial effects regarding the CVD risk, i.e. decreased LDL-cholesterol/HDL-253 
cholesterol ratio, with the consumption of modified milk fat obtained by feeding cows high-fat 254 
rapeseed cake (16% oil). 255 
By contrast, our study shows that the consumption of R-TFA up to 2.42% (L9 diet) of the daily 256 
energy intake has no significant effect on the evolution of the HDL concentration which is different 257 
from an IP-TFA intake (Katan et al., 1995). However, the differential effect between IP- and R-258 
TFA sources on the HDL parameter seems to disappear for higher TFA intake (3.5% total energy 259 
intake) (Motard-Belanger et al., 2008). Even so, our data suggest that whereas mild increase in R-260 
TFA/SFA ratio in milk fat may be beneficial compared to L0 diet, further increase in R-TFA/SFA 261 
ratio does not provide additional benefit regarding the CVD risk factors. Moreover the lack of 262 
beneficial effect of the L9 diet could also due to the huge increase in the trans 18:2-isomers. These 263 
isomers have been reported to be more deleterious than the trans 18:1-isomers (Baylin et al., 2003)  264 
, for a review see (Mozaffarian and Clarke, 2009)). 265 
 266 
During our clinical intervention, we found no significant effect of the consumption of these 3 267 
different diets on the HDL parameter. This result is in accordance with already published trials. 268 
Tricon et al. (Tricon et al., 2006) reported that the consumption for 6 weeks of a dairy product 269 
naturally enriched in cis-9,trans-11 CLA (0.2 g/d to 1.5 g/d) and trans-11 18:1 (0.8 g/d to 6.3 g/d) 270 
failed to alter plasma triacylglycerol, total cholesterol, LDL-cholesterol, and HDL-cholesterol 271 
concentrations and total to HDL cholesterol ratio,  in healthy middle aged-men. The lack of 272 
differences on the HDL parameter could be related to our calculation of the sample size. Indeed, to 273 
calculate the sample size, we use the predictive equation of HDL-cholesterol  (Yu et al., 1995) and 274 
on the other hand we decided that the predicted difference should be δ=2,17 mg/dL: it was perhaps 275 
a too small extend in the change in HDL concentrations. 276 
Moreover, our study was carried out in men and women. To our knowledge, there are few studies 277 
which assessed the effect of the consumption of modified dairy fat on female CVD risk factors. In 278 
our conditions, we found no gender effect, for the relation between the CVD risk factors and fatty 279 
acids profiles of dairy fat.  280 
To conclude, we confirm that the consumption of R-TFA at nutritional level (1.01 % L4 diet i.e. 281 
<2.0% of energy, the level recommended by the French authorities) have no adverse effect related 282 
to some cardiovascular risk factors whatever the gender, which is in accordance with most 283 
intervention studies (Motard-Belanger et al., 2008; Seidel et al., 2005)  and also with the recent 284 
epidemiological study (Jakobsen et al., 2008). Moreover, this clinical study underlines the fact that, 285 
cows’ feeding strategy consisting in decreasing the SFA/TFA ratio (less SFA (56.6%) and more 286 
total trans (12.16 %)) in fat does not bring any additional benefits regarding the CVD risk in 287 
healthy volunteers. 288 
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 Figure legends 
Figure 1 Study design. (Dietary questionnaire) 
 
Figure 2 Disposition of subjects (n=126) during the study. 
Table 1 Fatty acid composition of the different experimental dairy fats (g fatty acid/100g of fatty acids) 
Fatty acids Fatty acid composition  
 L0b L4 b L9 b 
C4:0 2.54 2.83 2.94 
C5:0 0.04 0.03 0.03 
C6:0 1.80 1.76 1.95 
C7:0 0.03 0.02 0.02 
C8:0 1.20 1.06 1.24 
C9:0 0.03 0.03 0.03 
C10:0 3.09 2.33 2.86 
C10:1 0.30 0.19 0.27 
C11:0 0.07 0.04 0.05 
C12:0 3.95 2.88 3.31 
C13:0 0.22 0.13 0.17 
C14:0 12.84 9.75 11.04 
C14:1 1.00 0.64 0.94 
C15:0 1.26 1.08 0.94 
C16:0 34.60 27.94 21.93 
C16:1 1.55 1.65 1.02 
C17:0 0.73 0.79 0.53 
C17:1 0.21 0.35 0.15 
C18:0 9.41 12.42 9.43 
C18:1 trans Total  2.53 3.49 9.50 
        trans-4 0.01 0.01 0.04 
        trans-5 0.01 0.01 0.03 
        trans-6/8 0.21 0.21 0.58 
        trans-9 0.21 0.23 0.45 
        trans-10 0.29 0.33 1.23 
        trans-11 1.00 1.81 4.26 
        trans-12 0.29 0.29 0.86 
        trans-13 0.51 0.59 2.04 
        trans-9+trans-10+trans-11 1.51 2.37 5.94 
C18:1 n-9 15.53 21.87 17.12 
C18:1 cis-14+trans-16 0.28 0.35 0.63 
C18:1 cis-15+C19:0 0.16 0.21 0.53 
Other cis-C18:1 isomers 0.94 0.97 1.49 
trans-C18:2 0.32 0.57 2.66 
CLA 0.42 0.67 1.86 
C18:2 n-6 1.34 1.31 2.06 
C18:3 n-3 0.22 0.59 1.22 
C20:0 0.11 0.13 0.07 
C20:2 n-6 0.01 0.01 0.02 
C20:3 n-6 0.06 0.04 0.05 
C20:4 n-6 0.09 0.07 0.08 
C20:5 n-3 0.03 0.08 0.04 
C22:0 0.04 0.05 0.02 
C24:0 0.02 0.03 0.02 
C22:5 0.05 0.09 0.05 
Other fatty acids 3.00 3.53 3.72 
Sum (12:0+14:0+16:0) 51.39 40.57 36.27 
Total saturated fatty acids 71.97 63.31 56.59 
Total cis-MUFA 19.52 25.66 20.99 
Total trans fatty acidsa 2.85 4.06 12.16 
Total cis-PUFA 2.21 2.87 5.37 
aSum of trans-18:1 and trans-18:2 acid isomers; Conjugated Linoleic Acid (CLA) are not taken into 
account in this calculation; bL0, L4, L9 see Method section, cis-MUFA: cis-monounsaturated fatty 
acids; cis-PUFA: cis-polyunsaturated fatty acids  
Table 2 Baseline characteristics (by study group) of subjects who completed the trial. 
Parameter L0 group L4 group L9 group p-Value 
Clinical     
Gender* (M/F) 18/18 18/17 18/18 0.990 
Age (y) 26 ±7 [12; 40] 25 ±6 [13; 37] 28 ±9 [10; 45] 0.394 
Waist (cm) 74.1±9.0 [56.6; 91.7] 74.4±8.1 [58.6; 90.2] 71.3±8.1 [55.3; 87.2] 0.997 
Body mass index (kg/m2) 21.7±2.7 [16.5; 26.9] 22.0±2.3 [17.5; 26.5] 21.9±2.5 [16.9; 26.8] 0.891 
Systolic blood pressure (mm Hg) 116±9 [97; 134] 116±8 [100; 132] 116±13 [91; 141] 0.997 
Diastolic blood pressure (mm Hg) 73±8 [58; 88] 71±9 [53; 89] 72±9 [54; 90] 0.654 
Resting heart rate (beat per min) 67±8 [51; 83] 64±7 [50; 78] 68±10 [48; 88] 0.122 
Glucose (mmol/L) 4.6±03 [4.0; 5.3] 4.6±0.4 [3.8; 5.5] 4.7±0.5 [3.7; 5.6] 0.919 
Bilirubin (µmol/L) 14±9 [-3; 32] 13±8 [-2; 29] 13±6 [1; 25] 0.709 
ASAT (UI/L) 23±5 [13; 32] 23±4 [14; 31] 23±5 [12; 33] 0.927 
ALAT (UI/L) 17±8 [1; 33] 18±9 [1; 35] 17±7 [3; 30] 0.685 
Phosphatase alkaline (UI/L) 58±14 [31; 85] 59±21 [18; 100] 56±13 [30; 81] 0.653 
γ-Glutamyl transpeptidase (UI/L) 14±7 [0; 28] 18±12 [-6; 42] 15±7 [0; 29] 0.135 
Na (mmol/L) 142±2 [138; 145] 141±2 [138; 145] 141±2 [138; 145] 0.572 
K (mmol/L) 4.3±0.3 [3.6; 4.9] 4.2±0.3 [3.7; 4.8] 4.2±0.3 [3.6; 4.8] 0.687 
Cl (mmol/L) 103±2 [100; 106] 103±2 [100; 106] 103±1 [100; 106] 0.919 
Urea (mmol/L) 5.1±1.2 [2.8; 7.3] 5.3±1.5 [2.4; 8.3] 4.9±1.3 [2.4; 7.5] 0.429 
Creatinin (µmol/L) 75±10 [56; 94] 78±11 [56; 100] 75±12 [52; 97] 0.354 
Erythrocytes (T/L) 4.87±0.38 [4.13; 5.61] 4.82±0.36 [4.11; 5.53] 4.79±0.41 [3.99; 5.58] 0.621 
Haemoglobin (g/dL) 14.3±1.2 [12.0; 16.6] 14.0±1.1 [12.0; 16.1] 14.0±1.2 [11.8; 16.3] 0.525 
Haematocrit (%) 42.3±3.1 [36.1; 48.4] 41.6±2.5 [36.8; 46.4] 41.6±3.0 [35.8; 47.4] 0.530 
Mean Globular Volume (fL) 86.8±2.5 [81.9; 91.7] 86.4±3.0 [80.6; 92.2] 87.1±3.8 [79.7; 94.5] 0.624 
Platelets (G/L) 224±38a [148; 299] 255±42 b [172; 337] 247±52 b [146; 349] 0.01 
Leukocytes (G/L) 5.96±1.36 [3.29; 8.63] 6.25±1.55 [3.22; 9.28] 5.68±1.28 [3.16; 8.19] 0.234 
Neutrophils (G/L) 3.12±1.17 [0.83; 5.40] 3.30±1.14 [1.07; 5.54] 2.98±0.90 [1.22; 4.74] 0.446 
Eosinophils (G/L) 0.16±0.10 [0.03; 0.35] 0.16±0.10 [0.03; 0.35] 0.17±0.16 [0.15; 0.49] 0.839 
Basophils (G/L) 0.02±0.02 [0.01; 0.06] 0.02±0.01 [0.00; 0.05] 0.03±0.01 [0.00; 0.05] 0.587 
Lymphocytes (G/L) 2.14±0.58 [1.00; 3.28] 2.23±0.73 [0.79; 3.66] 2.03±0.65 [0.76; 3.30] 0.454 
Monocytes (G/L) 0.52±0.13 [0.27; 0.77] 0.53±0.18 [0.19; 0.87] 0.48±0.13 [0.22; 0.74] 0.337 
Fasting chemical lipids     
HDL-C (mmol/L) 1.69±0.33 [1.03; 2.34] 1.76±0.50 [0.79; 2.74] 1.62±0.40 [0.84; 2.39] 0.348 
LDL-C (mmol/L) 2.34±0.67 [1.02; 3.66] 2.46±0.75 [0.99; 3.93] 2.35±0.79 [0.80; 3.91] 0.760 
Triacylglycerol (mmol/L) 0.81±0.25 [0.31; 1.30] 0.85±0.32 [0.23;1.47] 0.69±0.28 [0.13; 1.25] 0.052 
Cholesterol (mmol/L) 4.39±0.69 [3.05; 5.74] 4.61±0.82 [2.99; 6.22] 4.29±0.86 [2.59; 5.98] 0.226 
Values are expressed as mean ± SD and 95% confidence intervals [95% CIs]* Number of male and 
females, respectively. Data were analyzed by a one way ANOVA. 
 
Table 3 Mean daily intake and 95% confidence intervals [95% CIs] of energy and macronutrients in L0, L4 and L9 groups, at baseline and after the 3 
week intervention period (follow-up). 
  L0 group (n = 36) L4 group (n = 35) L9 group (n = 36) ANOVA 
 Baseline Follow-up Baseline Follow-up Baseline Follow-up Gender Diet Gender x Diet
 Mean ±SD [95% CIs] p p p 
Total Energy, kJ/d 8610±1404 
[-5858; 11361] 
8782±1602 
[-5642; 11923] 
8556±1884 
[-4864; 12249]
8583±1486 
[-5671; 11495]
8104±1539 
[-5086; 1121]
8375±1519 
[-5398; 11352] 
0.225 0.670 0.655 
Protein,  
%en 
14.8±3.0 
[-9.0; 20.6] 
14.9±2.9 
[-9.3 20.5] 
15.0±2.7 
[-9.7; 20.3] 
15.4±2.7 
[-10.2; 20.7] 
14.1±2.8 
[-8.6; 19.6] 
14.5±2.4 
[-9.8; 19.2] 
0.284 0.666 0.968 
Carbohydrate, %en 47.5±5.9 
[-36.0; 59.0] 
47.4±5.9 
[-35.9; 59.0] 
45.9±5.3 
[-35.5; 56.2] 
44.9±5.0 
[-36.0; 55.7] 
47.2±5.7 
[-35.9; 58.4] 
46.7±4.9 
[-37.2; 56.2] 
0.453 0.912 0.485 
Total Fat,  
%en  
37.7±5.4 
[-27.1; 48.2] 
37.7±5.0 
[-27.8; 47.5] 
39.2±5.0 
[-29.4; 49.0] 
38.7±5.1 
[-28.8; 48.6] 
38.8±5.4 
[-28.3; 49.3] 
38.8±4.8 
[-29.4; 48.2] 
0.805 0.876 0.612 
SFA, 
%en 
21.5±2.6 
[-16.4;26.6] 
21.3±2.8a 
[-15.8; 26.8] 
22.1±3.0 
[-16.2; 28.0] 
19.9±2.9 b 
[-14.2; 25.5] 
22.6±3.3 
[-16.1; 29.0] 
18.1±2.4 c 
[-13.4; 22.9] 
0.308 <0.0001 0.965 
MUFA,  
%en  
11.4±2.7 
[-6.0; 16.7] 
11.8±2.6 a 
[-6.7; 16.8] 
11.7±2.5 
[-6.9; 16.5] 
14.0±2.6 b 
[-9.0; 19.1] 
11.9±2.6 
[-6.7; 17.0] 
14.3±2.2 b 
[-10.1; 18.6] 
0.607 0.0003 0.904 
PUFA, 
%en 
3.6±1.3 
[-1.1; 6.1] 
3.6±1.1 a 
[-1.4; 5.7] 
3.5±1.2 
[-1.1; 5.9] 
3.9±1.3 b 
[-1.3; 6.4] 
3.6±1.2 
[-1.3; 5.9] 
5.2±1.0 c 
[-3.2; 7.1] 
0.380 <0.0001 0.531 
Total TFA* 
%en 
0.70±0.11  
[-0.49; 0.91] 
0.69±0.11 a 
[-0.47 ; 0.91] 
0.72±0.14 
[-0.45; 0.98] 
1.01±0.18 b 
[-0.65;1.36] 
0.75±0.13 
[-0.49; 1.01] 
3.10±0.55 c 
[-2.02; 4.18] 
0.169 <0.0001 0.148 
Total trans-18:1* 
%en 
0.62±0.10 
[-0.43; 0.81] 
0.61±0.10 a 
[-0.43 ; 0.81] 
0.64±0.12 
[-0.40; 0.87] 
0.87±0.16 b 
[-0.56; 1.17] 
0.67±0.12 
[-0.44; 0.90] 
2.42±0.43 c 
[-1.57; 3.27] 
0.236 <0.0001 0.173 
All values are means ± SD. Data (the difference between end of the intervention and baseline) were analyzed using a 2-way ANOVA with gender and diet as factors. 
Means in a row without common superscript letters differ. 
%en: % of total energy, SFA, saturated fatty acids; cis-MUFA: cis-monounsaturated fatty acids; cis-PUFA: cis-polyunsaturated fatty acids; TFA, trans fatty acids. *: 
this represents only the percentage of TFA and total trans-18:1 in the three different food items (butter, dessert cream, and cookies). 
Table 4 Serum lipids, lipoprotein, apolipoprotein concentrations, cholesterol ester transfer protein (CETP) activity and fibrinogen concentration in the 
three different groups (L0, L4 and L9 group) mean  and 95% confidence intervals [95% CIs]  at baseline and estimate mean effects after 3 weeks. 
Variable and subjects Baseline values1 Estimate mean effects2 p-Value   
 L0 group  (n = 36) L4 group  (n = 35) L9 group  (n = 36) L0 L4 L9 Diet Gender Interaction 
HDL-C (mmoL/L) 1.70 ± 0.44 [0.85; 2.56] 
1.74 ± 0.51 
[0.74; 2.74] 
1.59±0.32 
[0.97; 2.21] 
0.01±0.16 
[-0.31; 0.33] 
0.05±0.17 
[-0.29; 0.39] 
0.00±0.15 
[-0.30; 0.29] 0.378 0.457 0.965 
LDL-C (mmoL/L) 2.33 ± 0.77 [0.82; 3.83] 
2.65 ± 0.83 
[1.02; 4.28] 
2.55 ± 0.90 
[0.78; 4.32] 
0.11±0.33a 
[-0.53; 0.75] 
-0.14±0.38b 
[-0.72; 0.77] 
-0.07±0.42a,b 
[-0.89; 0.76] 0.040 0.759 0.386 
Total cholesterol 
(mmol/L) 
4.42 ± 0.78 
[2.88; 5.95] 
4.88 ± 0.86  
[3.19; 6.57] 
4.52 ± 0.93 
[2.70; 6.34] 
0.1±0.42a 
[-0.68; 0.95] 
-0.13±0.50b 
[-1.11; 0.85] 
-0.05±0.42a, b 
[-0.87; 0.77] 0.037 0.448 0.332 
TG (mmol/L) 0.85 ± 0.31 [0.24; 1.47] 
1.08 ± 0.53 
[0.04; 2.12] 
0.82 ± 0.29  
[0.25; 1.40] 
0.05 ± 0.27 
[-0.48; 0.57] 
-0.10 ± 0.46 
[-0.99; 0.80] 
0.04±0.35 
[-0.64; 0.72] 0.198 0.629 0.094 
ApoA1 (g/L) 1.52 ± 0.25 [1.04; 2.01] 
1.63 ± 0.33 
[0.98; 2.29] 
1.48 ± 0.20 
[1.09; 1.88] 
0.04±0.13 
[-0.21; 0.29] 
0.01±0.11 
[-0.20; 0.22] 
0.00±0.08 
[-0.16; 0.16] 0.387 0.980 0.168 
ApoB (g/L) 0.79 ± 0.19 [0.42; 1.16] 
0.88 ± 0.21 
[0.47; 1.28] 
0.81 ± 0.22 
[0.37; 1.24] 
0.02 ± 0.09 
[-0.15; 0.20] 
-0.03± 0.10 
[-0.22; 0.16] 
0.01± 0.12 
[-0.22; 0.24] 0.065 0.840 0.221 
LDL-C/HDL-C 1.47 ± 0.65 [0.21; 2.74] 
1.69 ± 0.70  
[0.31; 3.06] 
1.68 ± 0.73  
[0.25; 3.12] 
0.06 ± 0.22a
[-0.37; 0.50] 
-0.14 ± 0.36b
[-0.84; 0.57] 
0.00 ± 0.33a,b 
[-0.66; 0.65] 0.028 0.837 0.587 
Total cholesterol/HDL-C 2.73 ± 0.74
  
[1.27; 4.18] 
3.00 ± 0.85  
[1.33; 4.68] 
2.93 ± 0.79 
[1.39; 4.47] 
0.07 ± 0.28a 
[-0.47; 0.61] 
-0.18 ± 0.44b 
[-1.05; 0.68] 
0.01 ± 0.39a 
[-0.74; 0.77] 0.016 0.761 0.293 
ApoB/ApoA1 0.53 ± 0.15 [0.23; 0.84] 
0.56 ± 0.16 
[0.25; 0.87] 
0.55 ± 0.17 
[0.23; 0.87] 
0.00 ± 0.06 
[-0.12; 0.12] 
-0.03 ± 0.07 
[-0.16; 0.11] 
0.01 ± 0.08 
[-0.14; 0.16]] 0.133 0.782 0.577 
CETP activity 
(nmol/h/mL) 
16.87 ± 3.97 
[9.10; 24.66] 
17.04 ± 4.66 
[7.91; 26.18] 
18.12 ± 4.30 
[9.69; 26.56] 
0.23 ± 6.83 
[-13.15; 13.61] 
0.61 ± 8.39 
[-15.84; 17.07] 
0.03 ± 7.31 
[-14.29; 14.36] 0.944 0.630 0.701 
Fibrinogen (g/L) 2.68 ± 0.53 [1.64; 3.72] 
2.75 ± 0.57 
[1.64; 3.86] 
2.70 ± 0.53 
[1.65; 3.74] 
-0.56 ± 0.52 
[-1.58; 0.46] 
-0.49 ± 0.43 
[-1.34; 0.36] 
-0.50 ± 0.55 
[-1.59; 0.58] 0.843 0.458 0.744 
1means ± SD, 2 Estimate mean effects is defined as the difference between end of the intervention and baseline. Data are analyzed by using a two-ways anova. Means 
in a row without common superscript letters differ. 
 
Abbreviations 
ALT: Alanine aminotransférase 
AST: Aspartate aminotransférase 
βHCG: Human chorionic gonadotropin 
CETP: Cholesteryl ester transfer protein 
CPP: Comité de protection des personnes 
CRNH: Centre de recherche en nutrition humaine 
CRP: C reactive protein 
CVD: Cardiovascular disease 
DQ: Dietary Questionnaire 
EU: European Union 
γGT: Gamma glutamyltransférase 
HCV: Hepatitis C virus 
IP-TFA: Industrially produced trans fatty acids 
PHVO: Partially hydrogenated vegetable oils 
R-TFA: Ruminant trans fatty acids 
TFA: Trans fatty acids 
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